Logical Intelligence Introduces First Energy-Based Reasoning AI Model, Signals Early Steps Toward AGI, Adds Yann LeCun and Patrick Hillmann to Leadership
21.1.2026 19:21:00 CET | Business Wire | Press Release
Logical Intelligence, an artificial intelligence company developing energy-based (EBM) reasoning systems, today announced that Kona 1.0, its pioneering EBM for reasoning, will enter pilot programs with select partners in the energy, advanced manufacturing, and semiconductor industries later this quarter.
Logical Intelligence also released a live demonstration of Kona 1.0 on its website, beginning with head-to-head sudoku challenges against leading large language models. Additional demonstrations, including chess and Go, are planned. The company said the goal is to give researchers and the public a clear view into how energy-based reasoning differs from probabilistic systems.
“Kona learns by recognizing and correcting its own mistakes, rather than guessing the most likely answer,” said Eve Bodnia, founder and CEO of Logical Intelligence. “If general intelligence means the ability to reason across domains, learn from error, and improve without being retrained for each task, then we are seeing in Kona the first credible signs of AGI. It is not the end state, but it is a clear break from narrow AI. AGI as a finished state will not emerge from any single model class. It will require an interdependent ecosystem composed of EBMs, LLMs, world models, and others, working together.”
The company named Yann LeCun, former chief AI scientist at Meta, as founding chair of its Technical Research Board and appointed Patrick Hillmann, formerly a director at General Electric and previously Chief Strategy Officer at Binance, as Chief Strategy Officer. LeCun and Hillmann complement Logical Intelligence’s leadership team which also includes Fields Medalist Michael Freedman as Chief of Mathematics and ICPC World Champion and Facebook alumnus Vlad Isenbaev as Chief of AI.
“A major question in AI is how to perform reasoning,” said LeCun. “My opinion has always been that true reasoning should be formulated as an optimization problem. This is the basis of what I have called energy-based models: reasoning and inference by minimizing an energy function. Logical Intelligence is the first company to move EBM-based reasoning from a research concept to products, enabling a new breed of more reliable AI systems.”
Logical Intelligence develops AI systems targeted at applications where behavior must be provably correct rather than statistically likely, including advanced manufacturing, energy infrastructure, semiconductor verification, and robotics. Unlike language models that guess the most likely answer, the company’s energy-based systems work by mapping out what is allowed and what is not, then finding solutions that stay inside those boundaries. The architecture is aimed at sectors where certification, liability, and auditability are prerequisites for deployment.
Kona 1.0 extends the company’s existing work in formal verification and verified code generation, which has been used to prove the correctness of software components in adversarial and regulated settings. The new model is designed to reason over entire systems rather than isolated functions, allowing correctness guarantees to persist as systems evolve.
“AI is moving into sectors where failure results in material consequences,” said Hillmann. “Markets are demanding systems that can be certified and defended, not just optimized for performance. We’ll also be engaging early with policymakers and industry leaders to ensure this technology is deployed carefully, with clear rules so that Kona scales in a responsible manner.”
About the recent appointees
Yann LeCun is founding chair of the technical research board at Logical Intelligence, executive chair of AMI Labs, and a professor at NYU. He was the chief AI scientist of Meta, the founding director of Meta-FAIR, and of the NYU Center for Data Science. After a PhD from Sorbonne Université and research positions at AT&T and NEC, he joined NYU in 2003 and Meta in 2013. He received the 2018 ACM Turing Award for his work on AI. He is a member of the US National Academies and the French Académie des Sciences.
Patrick Hillmann is chief strategy officer for Logical Intelligence. Most recently, Hillmann was chief strategy officer at Binance, the world’s largest cryptocurrency exchange. Earlier, he was an executive in the crisis and risk practice and global head of innovation at Edelman, and served in executive roles at General Electric and the National Association of Manufacturers. Hillmann has an M.A. in international economic policy from the University of Wisconsin-Madison.
Michael Freedman is chief of mathematics at Logical Intelligence. Freedman was awarded the Fields Medal, the highest honor in mathematics, for his work on the 4-dimensional generalized Poincaré conjecture, a landmark discovery in topology. He has received many awards and honors, including Sloan and Guggenheim Fellowships, a MacArthur Fellowship, and the National Medal of Science. He is an elected member of the National Academy of Sciences, and a fellow of both the American Academy of Arts and Sciences and of the American Mathematical Society. The founding director of Microsoft’s quantum computing program, Freedman also has an appointment at Harvard’s Center for Mathematical Sciences and Applications.
Vlad Isenbaev is chief of AI for Logical Intelligence. A software engineer and research scientist with experience in generative AI and reinforcement learning, energy based models for robotics, he has held technical positions at Nuro, Cruise Automotion, and Facebook.
About Logical Intelligence
Logical Intelligence develops energy-based AI systems for reasoning in mission-critical environments, including energy, advanced manufacturing, industrial automation, financial automation, and hardware design. Its Aleph agent is available today for formal verification and automated code generation with machine-checkable proofs, while its forthcoming Kona platform extends this approach into frontier-scale energy-based reasoning for continuously verifiable systems.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120751310/en/
Contacts
media@logicalintelligence.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom